Product Description
Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany | Greece | Italy | Peru | Portugal
Approved Indications: None
Known Adverse Events: None
Company: Ji Xing Pharmaceuticals (Shanghai)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Miosis|Presbyopia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JX07001 | P3 |
Active, not recruiting |
Miosis|Presbyopia |
2024-08-19 |
|
JX07002 | P1 |
Completed |
Presbyopia |
2024-04-10 |
21% |
Safety Study | P3 |
Completed |
Miosis|Presbyopia |
2024-02-09 |
|
CLARITY | P3 |
Completed |
Presbyopia|Miosis |
2023-12-15 |